Targeting Mcl-1 for the therapy of cancer

Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1

(2012) Henry Zall et al.   Molecular Cancer

Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis

(2011) H. Sun et al.   BLOOD

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms

(2011) B. Holkova et al.   CLINICAL CANCER RESEARCH

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

(-)-Gossypol Suppresses the Growth of Human Prostate Cancer Xenografts via Modulating VEGF Signaling-Mediated Angiogenesis

(2011) X. Pang et al.   MOLECULAR CANCER THERAPEUTICS

SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction

(2011) Hiroyuki Inuzuka et al.   NATURE

Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity

(2011) R. Dash et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

(2010) D. Yecies et al.   BLOOD

Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24

(2010) Luni Emdad et al.   CANCER BIOLOGY & THERAPY

Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo

(2010) Clint Mitchell et al.   CANCER BIOLOGY & THERAPY

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies

(2010) Paul K. Paik et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells

(2010) Jingxuan Pan et al.   CANCER LETTERS

Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines

(2010) H. Xu et al.   CLINICAL CANCER RESEARCH

Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma

(2010) J. J. Hwang et al.   CLINICAL CANCER RESEARCH

mda-7/IL-24: A unique member of the IL-10 gene family promoting cancer-targeted toxicity

(2010) Rupesh Dash et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Mcl-1; the molecular regulation of protein function

(2010) Luke W. Thomas et al.   FEBS LETTERS

The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib

(2010) Hayato Hikita et al.   HEPATOLOGY

The BH3 α-Helical Mimic BH3-M6 Disrupts Bcl-XL, Bcl-2, and MCL-1 Protein-Protein Interactions with Bax, Bak, Bad, or Bim and Induces Apoptosis in a Bax- and Bim-dependent Manner

(2010) Aslamuzzaman Kazi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Gossypol Induces Death Receptor-5 through Activation of the ROS-ERK-CHOP Pathway and Sensitizes Colon Cancer Cells to TRAIL

(2010) Bokyung Sung et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

(2010) Wei-Gang Tong et al.   JOURNAL OF CLINICAL ONCOLOGY

BI-97C1, an Optically Pure Apogossypol Derivative as Pan-Active Inhibitor of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins

(2010) Jun Wei et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Pan-Bcl-2 Inhibitor (-)-Gossypol Triggers Autophagic Cell Death in Malignant Glioma

(2010) V. Voss et al.   MOLECULAR CANCER RESEARCH

Inhibition of Multiple Protective Signaling Pathways and Ad.5/3 Delivery Enhances mda-7/IL-24 Therapy of Malignant Glioma

(2010) Hossein A Hamed et al.   MOLECULAR THERAPY

A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy

(2010) W J Placzek et al.   Cell Death & Disease

GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy

(2010) N Heidari et al.   Cell Death & Disease

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

(2009) Rong Chen et al.   BLOOD

Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy

(2009) M. H. Kang et al.   CLINICAL CANCER RESEARCH

Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins

(2009) J. Wei et al.   MOLECULAR CANCER THERAPEUTICS

Cisplatin Enhances Protein Kinase R-Like Endoplasmic Reticulum Kinase- and CD95-Dependent Melanoma Differentiation-Associated Gene-7/Interleukin-24-Induced Killing in Ovarian Carcinoma Cells

(2009) A. Yacoub et al.   MOLECULAR PHARMACOLOGY

Eradication of Therapy-resistant Human Prostate Tumors Using an Ultrasound-guided Site-specific Cancer Terminator Virus Delivery Approach

(2009) Adelaide Greco et al.   MOLECULAR THERAPY

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

(2009) Martin Schwickart et al.   NATURE

Mimicking the BH3 domain to kill cancer cells

(2009) T Ni Chonghaile et al.   ONCOGENE

RNA Silencing of Mcl-1 Enhances ABT-737-Mediated Apoptosis in Melanoma: Role for a Caspase-8-Dependent Pathway

(2009) Angela M. Keuling et al.   PLoS One

Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048)

(2008) S. Kitada et al.   BLOOD

Inducing apoptosis and enhancing chemosensitivity to Gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell

(2008) San-Hua Wei et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax)

(2008) M. Konopleva et al.   CANCER RESEARCH

Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer

(2008) C. L. Hann et al.   CANCER RESEARCH

Mcl-1 is a potential therapeutic target in multiple types of cancer

(2008) C. Akgul   CELLULAR AND MOLECULAR LIFE SCIENCES

Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737

(2008) K. Okumura et al.   CLINICAL CANCER RESEARCH

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

(2008) A. D. Schimmer et al.   CLINICAL CANCER RESEARCH

Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa

(2008) Y. Meng et al.   MOLECULAR CANCER THERAPEUTICS

Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins

(2008) K E Tagscherer et al.   ONCOGENE

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas

(2008) K. D. Mason et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis

(2008) M. Sauane et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA